CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 85 enrolled
Drug / intervention
Valbenazinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03444038
NCT03444038Phase 2Completed
CompareCT.gov

Open-Label Safety and Tolerability Study of Optimized Doses of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome

Neurocrine Biosciences·interventional·Posted Feb 23, 2018·Updated Feb 23, 2022

In Brief

A Phase 2 clinical trial evaluating Valbenazine for Tourette Syndrome. Completed, enrolled 85 participants across 37 sites in 2 countries.

Detailed Summary

This is a Phase 2b, multicenter, open-label study to evaluate the safety and tolerability of optimized doses of NBI-98854 administered once daily for 24 weeks in pediatric subjects with Tourette Syndrome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTourette Syndrome
CountriesPuerto Rico, United States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedFeb 23, 2018
Enrollment StartFeb 8, 2018
Primary CompletionJul 12, 2019
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 8.4 years ago

Interventions

Valbenazinedrug

vesicular monoamine transporter 2 (VMAT2) inhibitor